Sanofi

Aventis Pharma S.a.

Aventis Pharmaceuticals Inc.

Aventis Pharma Limited

Rhone Poulenc Rorer

Sanofi-a Ventis Deutschland Gmbh

Sanofi-aventis

Axys Pharmaceuticals, Inc.

Frank Halley

Michel Tabart

Fabienne Thompson

Victor Certal

Laurent Schio

Fabrice Viviani

Bruno Filoche-Romme

Maurice Brollo

Baptiste Ronan

Youssef El-Ahmad

Iain M McLay

Eric Bacque

Andrew David Morley

Gary Mccort

Corinne Terrier

Francois Clerc

Jean-Christophe Carry

Michael L Edwards

Herve Bouchard

Patrick Mailliet

Gilles Doerflinger

Tahir Nadeem Majid

Paul Joseph Cox

Yulin Chiang

Dominique Damour

Gilles Dutruc-Rosset

Pascal Desmazeau

Yong Mi Choi-Sledeski

Neil Victor Harris

Hervé Bouchard

Conception Nemecek

Gregory Bernard Poli

Stephanie Deprets

David John Aldous

Andrew James Ratcliffe

David Fink

Gilbert Marciniak

Charles J Gardner

John O Link

Michael Graupe

Hartmut Strobel

Kurt Ritter

John W Patterson

Jiayao Li

Jean-Marie Ruxer

Sven Ruf

Franck Slowinski

Eric Didier

Maria Mendez-Perez

Hervé Minoux

Eric Nicolai

Catherine Souaille

Karl Andreas Karlsson

Barry Porter

Monsif Bouaboula

Youssef El Ahmad

Bernard Baudoin

Shelley Amendola

Brian L Pedgrift

Christopher D Edlin

Laurence Gauzy-Lazo

Clive McCarthy

Roger J Walsh

Peter Charles Astles

Timothy A Gillespy

Bertrand Vivet

William Joseph Hurst

Christopher Smith

William Arthur Metz, Jr

Dorothea Kominos

Marie-Pierre Cherrier

Chantal Carrez

Bao-Guo Huang

Annie Clauss

Bruno Filoche-Rommé

Joachim E Roehr

Sukanthini Thurairatnam

Juan Antonio Gamboa

Jean-Philippe Letallec

Patrick Mougenot

Justine Yeun Quai Lai

Olivier Houille

Joseph T Tsay

Andrew Paul Van Sickle

Daniel N A Bezard

Andre Zimmermann

Ann Marie Gelormini

Andrew Giovanni

Stephen Wayne Harnish

Odile Angouillant-Boniface

Antonio Ugolini

Alain Le Brun

Eykmar Fett

Fernando Camacho

Marcel Alasia

Luc Bertin

Stephen Dennis Pickett

Corinne Venot

Frédéric Petit

Andreas Paul Timm

Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof

The present disclosure relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (I-A), wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SERM-F represents a selective estrogen receptor modulator fragment comprising an aryl or heteroaryl group linked to the adjacent 'A' group. The disclosure also relates to the preparation and to the therapeutic uses of the compounds of formula (I-A) as inhibitors and degraders of estrogen receptors. 

Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a &#x2014;COOH, a &#x2014;OH or a &#x2014;OPO(OH)group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a &#x2014;OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a &#x2014;COOH, &#x2014;OH or &#x2014;OPO(OH)group, then R5 represents a hydrogen atom; when R5 represents a &#x2014;OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group;and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors.

Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

The invention relates to the novel materials of formula (I), wherein each of the substituents R, R1, R2, R3, R4 and R5 is as defined herein. The materials are useful as inhibitors of AKT(PKB) phosphorylation.

(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors

The invention relates to compounds of the formula:  or their racemic, enantiomeric or diastereoisomeric isomers, or pharmaceutically acceptable salts of the compounds of formula I or the racemic, enantiomeric or diasteroisomeric isomers.

1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof

The invention relates to a product of formula (I) where R1, R2, R3, and R4 are as defined herein, the therapeutic use of the product, a process to make the product, and a pharmaceutical composition comprising the product.

2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof

The invention relates to the novel products of formula (I): 

1H-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of AKT (PKB) phosphorylation

The invention relates to a compound of formula (I), where: Ris a phenyl group optionally substituted by one or more halogen atoms; Ris: a hydrogen atom or a halogen atom or a cyano group; a &#x2014;C(&#x2550;O)Y group where Y is a hydrogen atom, or a &#x2014;NHor &#x2014;ORgroup; a &#x2014;C(&#x2550;S)NHgroup; a &#x2014;C(&#x2550;NH)NH&#x2014;OH group; a &#x2014;CHOH or &#x2014;CHF group; a &#x2014;CH&#x2550;N&#x2014;OH group; a &#x2014;CH&#x2550;CHor &#x2014;C&#x2550;C&#x2014;Rgroup; a H or H Rgroup being a hydrogen or (C-C)alkyl group; Ris a hydrogen atom or (C-C)alkyl group; and Ris a &#x2014;NH, (C-C)alkyl, (C-C)fluoroalkyl or (C-C)cycloalkyl group. 

1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof

The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R'1; R is selected from the group comprising Formula (A&#x2032;), (B), (C), (D), or (E), with R1 and/or R&#x2032;1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO&#x2014;NH(alkyl), CON(alkyl)2, NH&#x2014;CO-alkyl, sulfonamide, NH&#x2014;S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or &#x2014;NH&#x2014;R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs. 

HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof

The disclosure relates to substituted pyrazolo-pyridines, compositions containing them, methods for the production thereof, and to their use as medicaments, in particular, as anticancer agents.

Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use

The invention relates to compounds of formula (I): wherein Ra, R1, Ar, L, A, W, Y, and Z are as defined in the disclosure; to compositions containing them; and to the preparation and use thereof, in particular as anticancer agents.

Substituted pyrrolopyridines, compositions containing them, manufacturing process therefor and use thereof

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

Growing community of inventors

Chaville, France

Frank Halley